The High Cost of Abandoning GLP1 Therapy for Obesity (Medium)

The article discusses the growing movement to deprescribe GLP-1 therapy for obesity due to cost concerns — but warns this is a shortsighted approach. Backed by robust clinical evidence, it argues that obesity is a chronic, relapsing condition and that discontinuing GLP-1s often leads to weight regain and worsened health outcomes. The real question, it concludes, isn’t whether we can afford to continue treatment — it’s whether we can afford not to.